WO2025008773 - MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITOR COMPOUNDS
National phase entry:
Publication Number
WO/2025/008773
Publication Date
09.01.2025
International Application No.
PCT/IB2024/056519
International Filing Date
03.07.2024
Title **
[English]
MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITOR COMPOUNDS
[French]
COMPOSÉS INHIBITEURS SPÉCIFIQUES DE TRANSCRIPTION MITOCHONDRIALE
Applicants **
LUNELLA BIOTECH, INC.
145 Richmond Road
Ottawa, Ontario K1Z 1A1, CA
Inventors
LISANTI, Michael P.
842 Wilmslow Road, Flat 27
Philip Godlee Lodge
Didsbury Village Greater Manchester M20 2DS, GB
SOTGIA, Federica
842 Wilmslow Road, Flat 27
Philip Godlee Lodge
Didsbury Village Greater Manchester M20 2DS, GB
KANGASMETSA, Jussi
119 Clay Farm Drive
Cambridge Cambridgeshire CB2 9BX, GB
DIPISA, Filippo
43 Greenwood Terrace
Salford Greater Manchester M5 3GH, GB
Priority Data
63/524,820
03.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1690 | |
| EPO | Filing, Examination | 8714 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 4960 |
Total: 16528 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Mitochondria specific transcription inhibitors may be used to target and eliminate cancer stem cells and may be used as therapeutic agents for the treatment of cancer, including reducing the likelihood of and/or preventing tumor recurrence and metastasis. The mitochondria specific transcription inhibitor compounds disclosed herein have demonstrated inhibition of tumorsphere forming capacity, migration and stemness-related signaling in cancer stem cells. These properties result from selective inhibiting of mitochondrial transcription targeting mitochondrial RNA polymerase (POLRMT) in cancer cells.[French]
La présente invention concerne des inhibiteurs spécifiques de transcription mitochondriale qui peuvent être utilisés pour cibler et éliminer des cellules souches cancéreuses et peuvent être utilisés en tant qu'agents thérapeutiques pour le traitement du cancer, notamment la réduction de la probabilité et/ou la prévention de la récurrence tumorale et de métastase. Les composés inhibiteurs spécifiques de transcription mitochondriale selon l'invention ont démontré l'inhibition de la capacité de formation de sphère tumorale, de la migration et de la signalisation liées aux cellules souches dans des cellules souches cancéreuses. Ces propriétés résultent d'une inhibition sélective de la transcription mitochondriale ciblant l'ARN polymérase mitochondriale (POLRMT) dans des cellules cancéreuses.